{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:49:08Z","timestamp":1784836148527,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the efficacy and safety of galcanezumab in patients with migraine in a real-world setting in Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Galcanezumab is the first anti-calcitonin gene-related peptide monoclonal antibody approved in Japan. To the best of our knowledge, no real-world studies on galcanezumab have been published in any international journal from Japan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively examined patients with migraine who received three doses of galcanezumab between August 2021 and February 2022 at the Keio University Hospital. We assessed changes in monthly migraine days, responder rate, and migraine-associated and premonitory symptoms. We also investigated injection site reactions and adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-two patients received three doses of galcanezumab during the study period. Compared with those at baseline, the monthly migraine days decreased by 5.9\u00a0days (95% confidence interval, 4.2\u20137.7) at 3\u00a0months. The 50% responder rate was 61.5% at 3\u00a0months. A total of 64.9%, 50.0%, and 63.9% of patients showed improvement in the severity of photophobia, phonophobia, and nausea\/vomiting, respectively. Premonitory symptoms without subsequent headache were reported in 62.5% of patients. Moreover, injection site reaction was the most common adverse event (34.6%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study revealed the efficacy and safety of galcanezumab for migraineurs in Japan. Galcanezumab also improved migraine-associated symptoms. However, despite a reduction in headaches, premonitory symptoms without subsequent headache were reported in\u2009&gt;\u200950% of the patients at 3\u00a0months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-03041-1","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T04:30:54Z","timestamp":1672461054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Tsubasa","family":"Takizawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chisato","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"3041_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, The L, Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: Findings from GBD2019. J Headache Pain. 2020;21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"key":"3041_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: A nationwide survey. Cephalalgia. 1997;17:15\u201322. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1701015.x.","journal-title":"Cephalalgia"},{"key":"3041_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0333102418779544","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Goadsby PJ. Discovery of CGRP in relation to migraine. Cephalalgia. 2019;39:331\u20132. https:\/\/doi.org\/10.1177\/0333102418779544.","journal-title":"Cephalalgia"},{"key":"3041_CR4","doi-asserted-by":"publisher","unstructured":"Sakai F, Ozeki A, Skljarevski V (2020) Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Rep 3.https:\/\/doi.org\/10.1177\/2515816320932573","DOI":"10.1177\/2515816320932573"},{"key":"3041_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","volume":"20","author":"K Hirata","year":"2021","unstructured":"Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf. 2021;20:721\u201333. https:\/\/doi.org\/10.1080\/14740338.2021.1866536.","journal-title":"Expert Opin Drug Saf"},{"key":"3041_CR6","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354. https:\/\/doi.org\/10.1177\/0333102418779543.","journal-title":"Cephalalgia"},{"key":"3041_CR7","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211\u201321. https:\/\/doi.org\/10.1212\/WNL.0000000000006640.","journal-title":"Neurology"},{"key":"3041_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, L\u00e1inez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814\u201325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30279-9.","journal-title":"Lancet Neurol"},{"key":"3041_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/03331024221076481","volume":"42","author":"S Kwon","year":"2022","unstructured":"Kwon S, Gil YE, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42:705\u201314. https:\/\/doi.org\/10.1177\/03331024221076481.","journal-title":"Cephalalgia"},{"key":"3041_CR10","unstructured":"Ministry of Health, Labour and Welfare (published 2021) Guidelines for promotion of optimal use of galcanezumab. Accessed 29 May 2022. https:\/\/www.pmda.go.jp\/files\/000240429.pdf"},{"key":"3041_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y.","journal-title":"J Headache Pain"},{"key":"3041_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-019-0975-2","volume":"20","author":"R Nichols","year":"2019","unstructured":"Nichols R, Skljarevski V, Dell\u2019Agnello G, Hundemer HP, Aurora SK. Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:22. https:\/\/doi.org\/10.1186\/s10194-019-0975-2.","journal-title":"J Headache Pain"},{"key":"3041_CR13","doi-asserted-by":"publisher","unstructured":"Diener HC, F\u00f6rderreuther S, Gaul C, Giese F, Hamann T, Holle-Lee D, J\u00fcrgens TP, Kamm K, Kraya T, Lampl C, May A, Reuter U, Scheffler A, Tfelt-Hansen P (2020) Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of neurology and the German Migraine and headache Society. Neurol Res Pract 2:11. https:\/\/doi.org\/10.1186\/s42466-020-00057-1","DOI":"10.1186\/s42466-020-00057-1"},{"key":"3041_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1\u201318. https:\/\/doi.org\/10.1111\/head.13456.","journal-title":"Headache"},{"key":"3041_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: A retrospective cohort study. Headache. 2020;60:2454\u201362. https:\/\/doi.org\/10.1111\/head.13956.","journal-title":"Headache"},{"key":"3041_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10072-020-04669-y","volume":"41","author":"F Vernieri","year":"2020","unstructured":"Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L, Costa CM, Fallacara A, Favoni V, Pierangeli G, Aguggia M, Bertuzzo D, Albanese M, Di Fiore P, Frediani F, Cevoli S, Barbanti P. Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). Neurol Sci. 2020;41:487\u20138. https:\/\/doi.org\/10.1007\/s10072-020-04669-y.","journal-title":"Neurol Sci"},{"key":"3041_CR17","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: A real-world evidence observational study. J Neurol. 2021;268:3789\u201398. https:\/\/doi.org\/10.1007\/s00415-021-10523-8.","journal-title":"J Neurol"},{"key":"3041_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: A multicenter prospective cohort study (the GARLIT study). J Headache Pain. 2021;22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1.","journal-title":"J Headache Pain"},{"key":"3041_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/ane.13599","volume":"145","author":"A L\u00f3pez-Bravo","year":"2022","unstructured":"L\u00f3pez-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine. Acta Neurol Scand. 2022;145:669\u201375. https:\/\/doi.org\/10.1111\/ane.13599.","journal-title":"Acta Neurol Scand"},{"key":"3041_CR20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1212\/01.wnl.0000052998.58526.a9","volume":"60","author":"NJ Giffin","year":"2003","unstructured":"Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine: An electronic diary study. Neurology. 2003;60:935\u201340. https:\/\/doi.org\/10.1212\/01.wnl.0000052998.58526.a9.","journal-title":"Neurology"},{"key":"3041_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1468-2982.2006.01075.x","volume":"26","author":"L Kelman","year":"2006","unstructured":"Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia. 2006;26:548\u201353. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01075.x.","journal-title":"Cephalalgia"},{"key":"3041_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-021-01215-9","volume":"22","author":"M Ament","year":"2021","unstructured":"Ament M, Day K, Stauffer VL, Skljarevski V, Rettiganti M, Pearlman E, Aurora SK. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain. 2021;22:6. https:\/\/doi.org\/10.1186\/s10194-021-01215-9.","journal-title":"J Headache Pain"},{"key":"3041_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/head.13446","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME. The effect of beginning treatment with Fremanezumab on headache and associated symptoms in the randomized Phase 2 study of high frequency episodic migraine: Post-hoc analyses on the first 3 weeks of treatment. Headache. 2019;59:383\u201393. https:\/\/doi.org\/10.1111\/head.13446.","journal-title":"Headache"},{"key":"3041_CR24","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"key":"3041_CR25","unstructured":"Muramatsu K, Seiryo N, Muramatsu Y, Miyaoka H, Fuse K, Yoshine F, Hosaka M, Katagiri A, Kutumi R (2009) Validation and utility of Japanese version of the GAD-7. PANMINERVA Medica. Abstracts Book, vol 51 20th World Congress on Psychosomatic Medicine, p 79"},{"key":"3041_CR26","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3389\/fpsyg.2018.01741","volume":"9","author":"S Doi","year":"2018","unstructured":"Doi S, Ito M, Takebayashi Y, Muramatsu K, Horikoshi M. Factorial validity and invariance of the 7-item generalized anxiety disorder scale (GAD-7) among populations with and without self-reported psychiatric diagnostic status. Front Psychol. 2018;9:1741. https:\/\/doi.org\/10.3389\/fpsyg.2018.01741.","journal-title":"Front Psychol"},{"key":"3041_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.genhosppsych.2018.03.007","volume":"52","author":"K Muramatsu","year":"2018","unstructured":"Muramatsu K, Miyaoka H, Kamijima K, Muramatsu Y, Tanaka Y, Hosaka M, Miwa Y, Fuse K, Yoshimine F, Mashima I, Shimizu N, Ito H, Shimizu E. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry. 2018;52:64\u20139. https:\/\/doi.org\/10.1016\/j.genhosppsych.2018.03.007.","journal-title":"Gen Hosp Psychiatry"},{"key":"3041_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-021-01330-7","volume":"22","author":"JC Ray","year":"2021","unstructured":"Ray JC, Allen P, Bacsi A, Bosco JJ, Chen L, Eller M, Kua H, Lim LL, Matharu MS, Monif M, Ruttledge M, Stark RJ, Hutton EJ. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021;22:121. https:\/\/doi.org\/10.1186\/s10194-021-01330-7.","journal-title":"J Headache Pain"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-03041-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03041-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T04:31:44Z","timestamp":1672461104000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-03041-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3041"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-03041-1","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Ethics Committee of the Keio University School of Medicine (approval number: 20211144). Patients were informed about this observational study via the institute\u2019s website, and they could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine, in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT serves as an advisor for Eli Lilly Japan, Otsuka, and Amgen. TT received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, and Santen Pharmaceutical and research funding from Eli Lilly Japan and Tsumura outside the submitted work. MS serves as an advisor for Eli Lilly Japan, Otsuka, and Amgen. MS received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, and Amgen and research funding from Otsuka outside the submitted work. JN received honoraria and research scholarships from Daiichi Sankyo. The remaining authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"512"}}